Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 176


Addendum to British Society for Haematology Guidelines on Investigation and Management of Antiphospholipid syndrome, 2012 (Br. J. Haematol. 2012; 157: 47-58): use of direct acting oral anticoagulants.

Arachchillage DRJ, Gomez K, Alikhan R, Anderson JAM, Lester W, Laffan M; British Society for Haematology Haemostasis and Thrombosis Taskforce.

Br J Haematol. 2020 Jan 13. doi: 10.1111/bjh.16308. [Epub ahead of print] No abstract available.


Multiyear Follow-up of AAV5-hFVIII-SQ Gene Therapy for Hemophilia A.

Pasi KJ, Rangarajan S, Mitchell N, Lester W, Symington E, Madan B, Laffan M, Russell CB, Li M, Pierce GF, Wong WY.

N Engl J Med. 2020 Jan 2;382(1):29-40. doi: 10.1056/NEJMoa1908490.


Patient experience of COPD care: outcomes from the British Lung Foundation Patient Passport.

Philip K, Gaduzo S, Rogers J, Laffan M, Hopkinson NS.

BMJ Open Respir Res. 2019 Oct 3;6(1):e000478. doi: 10.1136/bmjresp-2019-000478. eCollection 2019.


Use of Antithrombin Concentrate for Acquired Antithrombin Deficiency in Acutely Unwell Children Receiving Unfractionated Heparin.

Jayakody Arachchillage DR, Gaspar M, Makhecha S, Laffan M.

Semin Thromb Hemost. 2019 Nov;45(8):859-864. doi: 10.1055/s-0039-1700521. Epub 2019 Oct 21. No abstract available.


Partial rescue of naturally occurring active site factor X variants through decreased inhibition by tissue factor pathway inhibitor and antithrombin.

Ahnström J, Gierula M, Temenu J, Laffan MA, Lane DA.

J Thromb Haemost. 2020 Jan;18(1):136-150. doi: 10.1111/jth.14627. Epub 2019 Sep 20.


Limitations on point care APTT for monitoring of unfractionated heparin in intensive care patients.

Arachchillage DRJ, Vipond L, Laffan M.

Thromb Res. 2019 Sep;181:124-126. doi: 10.1016/j.thromres.2019.07.029. Epub 2019 Aug 1. No abstract available.


Pathogenesis and Management of Thrombotic Disease in Myeloproliferative Neoplasms.

Arachchillage DR, Laffan M.

Semin Thromb Hemost. 2019 Sep;45(6):604-611. doi: 10.1055/s-0039-1693477. Epub 2019 Aug 5.


Associations of genetically determined iron status across the phenome: A mendelian randomization study.

Gill D, Benyamin B, Moore LSP, Monori G, Zhou A, Koskeridis F, Evangelou E, Laffan M, Walker AP, Tsilidis KK, Dehghan A, Elliott P, Hyppönen E, Tzoulaki I.

PLoS Med. 2019 Jun 20;16(6):e1002833. doi: 10.1371/journal.pmed.1002833. eCollection 2019 Jun.


Germline mutations in the transcription factor IKZF5 cause thrombocytopenia.

Lentaigne C, Greene D, Sivapalaratnam S, Favier R, Seyres D, Thys C, Grassi L, Mangles S, Sibson K, Stubbs M, Burden F, Bordet JC, Armari-Alla C, Erber W, Farrow S, Gleadall N, Gomez K, Megy K, Papadia S, Penkett CJ, Sims MC, Stefanucci L, Stephens JC, Read RJ, Stirrups KE, Ouwehand WH, Laffan MA; NIHR BioResource, Frontini M, Freson K, Turro E.

Blood. 2019 Dec 5;134(23):2070-2081. doi: 10.1182/blood.2019000782.


NICE NG89 recommendations for extended pharmacological thromboprophylaxis - is it justified and is it cost effective: a rebuttal from the British Society for Haematology.

Lester W, Gomez K, Shapiro S, Dabhi K, Laffan M.

Br J Haematol. 2019 Sep;186(5):790-791. doi: 10.1111/bjh.16007. Epub 2019 Jun 5. No abstract available.


Utility of fibrinogen in the coagulation screen.

Tham C, Lee K, Laffan M.

Br J Haematol. 2019 Sep;186(5):e137-e139. doi: 10.1111/bjh.15978. Epub 2019 May 16. No abstract available.


Diagnostic high-throughput sequencing of 2396 patients with bleeding, thrombotic, and platelet disorders.

Downes K, Megy K, Duarte D, Vries M, Gebhart J, Hofer S, Shamardina O, Deevi SVV, Stephens J, Mapeta R, Tuna S, Al Hasso N, Besser MW, Cooper N, Daugherty L, Gleadall N, Greene D, Haimel M, Martin H, Papadia S, Revel-Vilk S, Sivapalaratnam S, Symington E, Thomas W, Thys C, Tolios A, Penkett CJ; NIHR BioResource, Ouwehand WH, Abbs S, Laffan MA, Turro E, Simeoni I, Mumford AD, Henskens YMC, Pabinger I, Gomez K, Freson K.

Blood. 2019 Dec 5;134(23):2082-2091. doi: 10.1182/blood.2018891192.


The top 10 research priorities in bleeding disorders: a James Lind Alliance Priority Setting Partnership.

Shapiro S, Stephensen D, Camp C, Carroll L, Collins P, Elston D, Gallagher P, Khair K, McKeown W, O'Hara J, Stanworth S, Waterman A, Woollard L, Upadhyaya S, Laffan M.

Br J Haematol. 2019 Aug;186(4):e98-e100. doi: 10.1111/bjh.15928. Epub 2019 Apr 23. No abstract available.


The heparin binding domain of von Willebrand factor binds to growth factors and promotes angiogenesis in wound healing.

Ishihara J, Ishihara A, Starke RD, Peghaire CR, Smith KE, McKinnon TAJ, Tabata Y, Sasaki K, White MJV, Fukunaga K, Laffan MA, Lutolf MP, Randi AM, Hubbell JA.

Blood. 2019 Jun 13;133(24):2559-2569. doi: 10.1182/blood.2019000510. Epub 2019 Apr 11.


Patterns of breathlessness and associated consulting behaviour: results of an online survey.

Elbehairy AF, Quint JK, Rogers J, Laffan M, Polkey MI, Hopkinson NS.

Thorax. 2019 Aug;74(8):814-817. doi: 10.1136/thoraxjnl-2018-212950. Epub 2019 Apr 8.


Evaluation of von Willebrand factor concentrates by platelet adhesion to collagen using an in vitro flow assay.

Riddell A, Vinayagam S, Gomez K, Laffan M, McKinnon T.

Res Pract Thromb Haemost. 2018 Dec 7;3(1):126-135. doi: 10.1002/rth2.12166. eCollection 2019 Jan.


The ADAMTS13-VWF axis is dysregulated in chronic thromboembolic pulmonary hypertension.

Newnham M, South K, Bleda M, Auger WR, Barberà JA, Bogaard H, Bunclark K, Cannon JE, Delcroix M, Hadinnapola C, Howard LS, Jenkins D, Mayer E, Ng C, Rhodes CJ, Screaton N, Sheares K, Simpson MA, Southwood M, Su L, Taboada D, Traylor M, Trembath RC, Villar SS, Wilkins MR, Wharton J, Gräf S, Pepke-Zaba J, Laffan M, Lane DA, Morrell NW, Toshner M.

Eur Respir J. 2019 Mar 28;53(3). pii: 1801805. doi: 10.1183/13993003.01805-2018. Print 2019 Mar.


Genetically Determined Platelet Count and Risk of Cardiovascular Disease.

Gill D, Monori G, Georgakis MK, Tzoulaki I, Laffan M.

Arterioscler Thromb Vasc Biol. 2018 Dec;38(12):2862-2869. doi: 10.1161/ATVBAHA.118.311804.


Efficacy and safety of prothrombin complex concentrate in patients treated with rivaroxaban or apixaban compared to warfarin presenting with major bleeding.

Arachchillage DRJ, Alavian S, Griffin J, Gurung K, Szydlo R, Karawitage N, Laffan M.

Br J Haematol. 2019 Mar;184(5):808-816. doi: 10.1111/bjh.15705. Epub 2018 Dec 4.


Thrombophilia in non-thrombotic chronic venous disease of the lower limb - a systematic review.

Tan MKH, Onida S, Laffan M, Davies AH.

Br J Haematol. 2018 Dec;183(5):703-716. doi: 10.1111/bjh.15692.


Genetically Determined FXI (Factor XI) Levels and Risk of Stroke.

Gill D, Georgakis MK, Laffan M, Sabater-Lleal M, Malik R, Tzoulaki I, Veltkamp R, Dehghan A.

Stroke. 2018 Nov;49(11):2761-2763. doi: 10.1161/STROKEAHA.118.022792.


Phenotype description and response to thrombopoietin receptor agonist in DIAPH1-related disorder.

Westbury SK, Downes K, Burney C, Lozano ML, Obaji SG, Toh CH, Sevivas T, Morgan NV, Erber WN, Kempster C, Moore SF, Thys C, Papadia S, Ouwehand WH; NIHR BioResource–Rare Diseases, Laffan MA, Gomez K, Freson K, Rivera J, Mumford AD.

Blood Adv. 2018 Sep 25;2(18):2341-2346. doi: 10.1182/bloodadvances.2018020370. No abstract available.


The use of viscoelastic haemostatic assays in the management of major bleeding: A British Society for Haematology Guideline.

Curry NS, Davenport R, Pavord S, Mallett SV, Kitchen D, Klein AA, Maybury H, Collins PW, Laffan M.

Br J Haematol. 2018 Sep;182(6):789-806. doi: 10.1111/bjh.15524. Epub 2018 Aug 2. No abstract available.


Clinical bleeding and thrombin generation in admissions to critical care with prolonged prothrombin time: an exploratory study.

Stanworth SJ, Desborough MJR, Simons G, Seeney F, Powter G, MacDonald S, McKechnie S, Green L, Young N, Walsh T, Laffan MA.

Transfusion. 2018 Jun;58(6):1388-1398. doi: 10.1111/trf.14605. Epub 2018 Apr 10.


Intracranial Hemorrhage and Early Mortality in Patients Receiving Extracorporeal Membrane Oxygenation for Severe Respiratory Failure.

Arachchillage DRJ, Passariello M, Laffan M, Aw TC, Owen L, Banya W, Trimlett R, Morgan C, Patel BV, Pepper J, Ledot S.

Semin Thromb Hemost. 2018 Apr;44(3):276-286. doi: 10.1055/s-0038-1636840. Epub 2018 Mar 22. Review.


AAV5-Factor VIII Gene Transfer in Severe Hemophilia A.

Rangarajan S, Walsh L, Lester W, Perry D, Madan B, Laffan M, Yu H, Vettermann C, Pierce GF, Wong WY, Pasi KJ.

N Engl J Med. 2017 Dec 28;377(26):2519-2530. doi: 10.1056/NEJMoa1708483. Epub 2017 Dec 9.


Can you grow out of von Willebrand disease?

Laffan M.

Haemophilia. 2017 Nov;23(6):807-809. doi: 10.1111/hae.13325. No abstract available.


Corrigendum: Drug therapy in anticoagulation: which drug for which patient?

Millar CM, Laffan MA.

Clin Med (Lond). 2017 Jul;17(4):347-349. doi: 10.7861/clinmedicine.17-4-347a. No abstract available.


Should we abandon the APTT for monitoring unfractionated heparin?

Arachchillage DRJ, Kamani F, Deplano S, Banya W, Laffan M.

Thromb Res. 2017 Sep;157:157-161. doi: 10.1016/j.thromres.2017.07.006. Epub 2017 Jul 6.


The Effect of Iron Status on Risk of Coronary Artery Disease: A Mendelian Randomization Study-Brief Report.

Gill D, Del Greco M F, Walker AP, Srai SKS, Laffan MA, Minelli C.

Arterioscler Thromb Vasc Biol. 2017 Sep;37(9):1788-1792. doi: 10.1161/ATVBAHA.117.309757. Epub 2017 Jul 6.


Quality assurance and tests of platelet function.

Jennings I, Perry D, Watson H, Alikhan R, Laffan M, Gomez K, Kitchen S, Walker I; Haemostasis and Thrombosis Task Force of the British Society for Haematology & UK NEQAS for Blood Coagulation.

Br J Haematol. 2018 May;181(4):560-561. doi: 10.1111/bjh.14668. Epub 2017 Jun 27. No abstract available.


Expanded repertoire of RASGRP2 variants responsible for platelet dysfunction and severe bleeding.

Westbury SK, Canault M, Greene D, Bermejo E, Hanlon K, Lambert MP, Millar CM, Nurden P, Obaji SG, Revel-Vilk S, Van Geet C, Downes K, Papadia S, Tuna S, Watt C; NIHR BioResource–Rare Diseases Consortium, Freson K, Laffan MA, Ouwehand WH, Alessi MC, Turro E, Mumford AD.

Blood. 2017 Aug 24;130(8):1026-1030. doi: 10.1182/blood-2017-03-776773. Epub 2017 Jun 21.


Can Mean Platelet Volume Be Used as a Predictor of Vascular Disease? Problems and Pitfalls.

Arachchillage DRJ, Laffan M.

Semin Thromb Hemost. 2017 Sep;43(6):599-608. doi: 10.1055/s-0037-1603360. Epub 2017 Jun 13. Review. No abstract available.


Drug therapy in anticoagulation: which drug for which patient?

Millar CM, Laffan MA.

Clin Med (Lond). 2017 Jun;17(3):233-244. doi: 10.7861/clinmedicine.17-3-233. Erratum in: Clin Med (Lond). 2017 Jul;17 (4):347-349. Dosage error in article text.


ADAMTS-13 glycans and conformation-dependent activity.

Nowak AA, O'Brien HER, Henne P, Doerr A, Vanhoorelbeke K, Laffan MA, McKinnon TAJ.

J Thromb Haemost. 2017 Jun;15(6):1155-1166. doi: 10.1111/jth.13688. Epub 2017 Apr 27.


Pathogenesis and management of antiphospholipid syndrome.

Arachchillage DRJ, Laffan M.

Br J Haematol. 2017 Jul;178(2):181-195. doi: 10.1111/bjh.14632. Epub 2017 Mar 24. Review.


Rare variants in GP1BB are responsible for autosomal dominant macrothrombocytopenia.

Sivapalaratnam S, Westbury SK, Stephens JC, Greene D, Downes K, Kelly AM, Lentaigne C, Astle WJ, Huizinga EG, Nurden P, Papadia S, Peerlinck K, Penkett CJ, Perry DJ, Roughley C, Simeoni I, Stirrups K, Hart DP, Tait RC, Mumford AD; NIHR BioResource, Laffan MA, Freson K, Ouwehand WH, Kunishima S, Turro E.

Blood. 2017 Jan 26;129(4):520-524. doi: 10.1182/blood-2016-08-732248. Epub 2016 Nov 14.


Epigenome-wide association study of body mass index, and the adverse outcomes of adiposity.

Wahl S, Drong A, Lehne B, Loh M, Scott WR, Kunze S, Tsai PC, Ried JS, Zhang W, Yang Y, Tan S, Fiorito G, Franke L, Guarrera S, Kasela S, Kriebel J, Richmond RC, Adamo M, Afzal U, Ala-Korpela M, Albetti B, Ammerpohl O, Apperley JF, Beekman M, Bertazzi PA, Black SL, Blancher C, Bonder MJ, Brosch M, Carstensen-Kirberg M, de Craen AJ, de Lusignan S, Dehghan A, Elkalaawy M, Fischer K, Franco OH, Gaunt TR, Hampe J, Hashemi M, Isaacs A, Jenkinson A, Jha S, Kato N, Krogh V, Laffan M, Meisinger C, Meitinger T, Mok ZY, Motta V, Ng HK, Nikolakopoulou Z, Nteliopoulos G, Panico S, Pervjakova N, Prokisch H, Rathmann W, Roden M, Rota F, Rozario MA, Sandling JK, Schafmayer C, Schramm K, Siebert R, Slagboom PE, Soininen P, Stolk L, Strauch K, Tai ES, Tarantini L, Thorand B, Tigchelaar EF, Tumino R, Uitterlinden AG, van Duijn C, van Meurs JB, Vineis P, Wickremasinghe AR, Wijmenga C, Yang TP, Yuan W, Zhernakova A, Batterham RL, Smith GD, Deloukas P, Heijmans BT, Herder C, Hofman A, Lindgren CM, Milani L, van der Harst P, Peters A, Illig T, Relton CL, Waldenberger M, Järvelin MR, Bollati V, Soong R, Spector TD, Scott J, McCarthy MI, Elliott P, Bell JT, Matullo G, Gieger C, Kooner JS, Grallert H, Chambers JC.

Nature. 2017 Jan 5;541(7635):81-86. doi: 10.1038/nature20784. Epub 2016 Dec 21.


A low balance between microparticles expressing tissue factor pathway inhibitor and tissue factor is associated with thrombosis in Behçet's Syndrome.

Khan E, Ambrose NL, Ahnström J, Kiprianos AP, Stanford MR, Eleftheriou D, Brogan PA, Mason JC, Johns M, Laffan MA, Haskard DO.

Sci Rep. 2016 Dec 7;6:38104. doi: 10.1038/srep38104.


Thromboelastography (TEG®) demonstrates that tinzaparin 4500 international units has no detectable anticoagulant activity after caesarean section.

Griffiths S, Woo C, Mansoubi V, Riccoboni A, Sabharwal A, Napier S, Columb M, Laffan M, Stocks G.

Int J Obstet Anesth. 2017 Feb;29:50-56. doi: 10.1016/j.ijoa.2016.10.001. Epub 2016 Oct 8.


Von Willebrand factor and angiogenesis: basic and applied issues.

Randi AM, Laffan MA.

J Thromb Haemost. 2017 Jan;15(1):13-20. doi: 10.1111/jth.13551. Review.


N-linked glycans within the A2 domain of von Willebrand factor modulate macrophage-mediated clearance.

Chion A, O'Sullivan JM, Drakeford C, Bergsson G, Dalton N, Aguila S, Ward S, Fallon PG, Brophy TM, Preston RJ, Brady L, Sheils O, Laffan M, McKinnon TA, O'Donnell JS.

Blood. 2016 Oct 13;128(15):1959-1968. Epub 2016 Aug 23.


Dietary supplement use and nosebleeds in hereditary haemorrhagic telangiectasia - an observational study.

Chamali B, Finnamore H, Manning R, Laffan MA, Hickson M, Whelan K, Shovlin CL.

Intractable Rare Dis Res. 2016 May;5(2):109-13. doi: 10.5582/irdr.2016.01019.


Inherited platelet disorders: toward DNA-based diagnosis.

Lentaigne C, Freson K, Laffan MA, Turro E, Ouwehand WH; BRIDGE-BPD Consortium and the ThromboGenomics Consortium.

Blood. 2016 Jun 9;127(23):2814-23. doi: 10.1182/blood-2016-03-378588. Epub 2016 Apr 19. Review.


A high-throughput sequencing test for diagnosing inherited bleeding, thrombotic, and platelet disorders.

Simeoni I, Stephens JC, Hu F, Deevi SV, Megy K, Bariana TK, Lentaigne C, Schulman S, Sivapalaratnam S, Vries MJ, Westbury SK, Greene D, Papadia S, Alessi MC, Attwood AP, Ballmaier M, Baynam G, Bermejo E, Bertoli M, Bray PF, Bury L, Cattaneo M, Collins P, Daugherty LC, Favier R, French DL, Furie B, Gattens M, Germeshausen M, Ghevaert C, Goodeve AC, Guerrero JA, Hampshire DJ, Hart DP, Heemskerk JW, Henskens YM, Hill M, Hogg N, Jolley JD, Kahr WH, Kelly AM, Kerr R, Kostadima M, Kunishima S, Lambert MP, Liesner R, López JA, Mapeta RP, Mathias M, Millar CM, Nathwani A, Neerman-Arbez M, Nurden AT, Nurden P, Othman M, Peerlinck K, Perry DJ, Poudel P, Reitsma P, Rondina MT, Smethurst PA, Stevenson W, Szkotak A, Tuna S, van Geet C, Whitehorn D, Wilcox DA, Zhang B, Revel-Vilk S, Gresele P, Bellissimo DB, Penkett CJ, Laffan MA, Mumford AD, Rendon A, Gomez K, Freson K, Ouwehand WH, Turro E.

Blood. 2016 Jun 9;127(23):2791-803. doi: 10.1182/blood-2015-12-688267. Epub 2016 Apr 15.


Defects in TRPM7 channel function deregulate thrombopoiesis through altered cellular Mg(2+) homeostasis and cytoskeletal architecture.

Stritt S, Nurden P, Favier R, Favier M, Ferioli S, Gotru SK, van Eeuwijk JM, Schulze H, Nurden AT, Lambert MP, Turro E, Burger-Stritt S, Matsushita M, Mittermeier L, Ballerini P, Zierler S, Laffan MA, Chubanov V, Gudermann T, Nieswandt B, Braun A.

Nat Commun. 2016 Mar 29;7:11097. doi: 10.1038/ncomms11097.


A dominant gain-of-function mutation in universal tyrosine kinase SRC causes thrombocytopenia, myelofibrosis, bleeding, and bone pathologies.

Turro E, Greene D, Wijgaerts A, Thys C, Lentaigne C, Bariana TK, Westbury SK, Kelly AM, Selleslag D, Stephens JC, Papadia S, Simeoni I, Penkett CJ, Ashford S, Attwood A, Austin S, Bakchoul T, Collins P, Deevi SV, Favier R, Kostadima M, Lambert MP, Mathias M, Millar CM, Peerlinck K, Perry DJ, Schulman S, Whitehorn D, Wittevrongel C; BRIDGE-BPD Consortium, De Maeyer M, Rendon A, Gomez K, Erber WN, Mumford AD, Nurden P, Stirrups K, Bradley JR, Raymond FL, Laffan MA, Van Geet C, Richardson S, Freson K, Ouwehand WH.

Sci Transl Med. 2016 Mar 2;8(328):328ra30. doi: 10.1126/scitranslmed.aad7666. Epub 2016 Mar 2.


A gain-of-function variant in DIAPH1 causes dominant macrothrombocytopenia and hearing loss.

Stritt S, Nurden P, Turro E, Greene D, Jansen SB, Westbury SK, Petersen R, Astle WJ, Marlin S, Bariana TK, Kostadima M, Lentaigne C, Maiwald S, Papadia S, Kelly AM, Stephens JC, Penkett CJ, Ashford S, Tuna S, Austin S, Bakchoul T, Collins P, Favier R, Lambert MP, Mathias M, Millar CM, Mapeta R, Perry DJ, Schulman S, Simeoni I, Thys C; BRIDGE-BPD Consortium, Gomez K, Erber WN, Stirrups K, Rendon A, Bradley JR, van Geet C, Raymond FL, Laffan MA, Nurden AT, Nieswandt B, Richardson S, Freson K, Ouwehand WH, Mumford AD.

Blood. 2016 Jun 9;127(23):2903-14. doi: 10.1182/blood-2015-10-675629. Epub 2016 Feb 24.


Site-specific analysis of von Willebrand factor O-glycosylation.

Solecka BA, Weise C, Laffan MA, Kannicht C.

J Thromb Haemost. 2016 Apr;14(4):733-46. doi: 10.1111/jth.13260. Epub 2016 Feb 17.

Supplemental Content

Loading ...
Support Center